secwatch.observer — SEC 8-K summary
======================================

Issuer:     Gain Therapeutics, Inc. (GANX)
CIK:        0001819411
Form:       8-K
Filed at:   2024-07-09T23:59:59+00:00
Accession:  0001104659-24-078600
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Gain Therapeutics completes MAD dosing for GT-02287 Phase 1; no SAEs, on track for Q4 2024 patient trial
--------------------------------------------------------------------------------

- Completed dosing in MAD part of Phase 1 study of GT-02287 for Parkinson's disease; no discontinuations or serious adverse events.
- GT-02287 well tolerated up to highest planned dose; 90% of adverse events mild, 10% moderate, no Grade 3+ events.
- Topline data expected mid-August after database lock; full safety and PK data to be presented at future congress.
- On track to initiate clinical trial in Parkinson's disease patients by Q4 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819411/000110465924078600/0001104659-24-078600-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819411/000110465924078600/tm2419145d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-078600

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer